Laurus Labs Ltd

Laurus Labs Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Laurus Labs Ltd

₹ 1,101 -0.47%
30 Apr - close price
lauruslabs.com BSE: 540222 NSE: LAURUSLABS
About

Founded in 2005, Laurus Labs is a research-driven pharmaceutical and biotechnology company having a global leadership
position in select Active Pharmaceutical Ingredients (APIs) including anti-retroviral, oncology drugs (including High Potent APIs), Cardiovascular, and Gastro therapeutics. They also offer integrated CMO and CDMO services to Global Innovators from Clinical phase drug development to commercial manufacturing.
Laurus employs 6,500+ people, including around 1,050+ scientists, at more than 11 facilities approved by global agencies USFDA, WHO-Geneva, Japan-PDMA, UK-MHRA, EMA, TGA etc. [1]

Key Points

Business Segments
1) Generic API (46% in 9M FY25 vs 41% in FY22): [1] [2] The company has one of the largest HiPotent API manufacturing capacities in India and is the world's leading third-party supplier of antiretroviral APIs. Its portfolio includes antiretrovirals, oncology, steroids, hormones, and cardiovascular APIs, serving global generic pharmaceutical companies. Segment revenue declined by 3% YoY in 9M FY25 due to ARV capacity reallocation towards high-yield, long-term business opportunities. [3] [1]

Website BSE NSE
  • Market Cap ₹ 59,436 Cr.
  • Current Price ₹ 1,101
  • High / Low ₹ 1,145 / 572
  • Stock P/E 80.3
  • Book Value ₹ 97.3
  • Dividend Yield 0.18 %
  • ROCE 15.9 %
  • ROE 15.1 %
  • Face Value ₹ 2.00
Edit ratios

Pros

Cons

  • Stock is trading at 11.3 times its book value
  • The company has delivered a poor sales growth of 5.01% over past five years.
  • Company has a low return on equity of 9.72% over last 3 years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE 500 BSE Healthcare Nifty 500 Nifty Pharma Nifty Midcap 100

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
1,279 1,108 1,158 1,132 1,415 1,117 1,185 1,265 1,650 1,433 1,567 1,509 1,580
1,027 980 978 962 1,143 956 1,003 1,059 1,255 1,105 1,177 1,164 1,205
Operating Profit 252 128 181 170 271 161 182 206 395 327 390 346 375
OPM % 20% 12% 16% 15% 19% 14% 15% 16% 24% 23% 25% 23% 24%
6 7 6 11 24 9 12 7 72 22 28 14 13
Interest 41 33 38 38 42 41 45 48 49 44 34 31 34
Depreciation 81 84 85 87 89 91 91 89 88 94 96 94 95
Profit before tax 137 17 63 57 164 39 58 77 330 211 289 234 259
Tax % 25% 24% 26% 25% 26% 26% 27% 25% 24% 25% 25% 25% 26%
102 13 47 43 121 29 42 57 252 158 216 175 192
EPS in Rs 1.90 0.24 0.87 0.79 2.25 0.53 0.79 1.06 4.67 2.93 4.00 3.24 3.55
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
1,326 1,775 1,892 2,027 2,236 2,797 4,769 4,707 5,773 4,812 5,217 6,089
1,121 1,402 1,478 1,618 1,884 2,226 3,258 3,421 4,292 4,062 4,273 4,651
Operating Profit 205 372 414 409 352 571 1,511 1,286 1,482 751 944 1,438
OPM % 15% 21% 22% 20% 16% 20% 32% 27% 26% 16% 18% 24%
34 4 32 28 15 5 26 20 16 47 100 77
Interest 106 111 97 75 86 88 66 96 146 151 182 143
Depreciation 61 86 104 121 161 184 197 235 301 345 359 379
Profit before tax 72 180 245 241 121 304 1,275 975 1,051 301 504 994
Tax % -2% 19% 18% 28% 22% 12% 25% 23% 28% 26% 24% 26%
74 145 200 173 95 267 956 750 760 224 380 740
EPS in Rs 9.47 18.36 3.78 3.27 1.78 5.00 17.82 13.96 14.12 4.15 7.05 13.72
Dividend Payout % 0% 2% 8% 9% 17% 10% 11% 14% 14% 19% 17% 9%
Compounded Sales Growth
10 Years: 13%
5 Years: 5%
3 Years: 2%
TTM: 17%
Compounded Profit Growth
10 Years: 18%
5 Years: -5%
3 Years: -1%
TTM: 118%
Stock Price CAGR
10 Years: %
5 Years: 18%
3 Years: 51%
1 Year: 77%
Return on Equity
10 Years: 16%
5 Years: 14%
3 Years: 10%
Last Year: 15%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 16 16 106 106 106 107 107 107 108 108 108 108
Reserves 645 790 1,250 1,407 1,484 1,709 2,605 3,281 3,949 4,099 4,456 5,144
888 1,081 808 947 1,009 1,051 1,411 1,653 1,714 2,110 2,380 2,080
344 342 509 547 718 872 1,502 1,567 1,187 1,351 1,643 2,208
Total Liabilities 1,893 2,229 2,673 3,008 3,318 3,739 5,625 6,609 6,958 7,667 8,587 9,540
801 1,014 1,193 1,448 1,599 1,694 1,818 2,186 2,884 3,036 2,888 3,041
CWIP 107 70 143 163 107 67 324 755 357 156 336 569
Investments 19 26 51 52 58 58 319 362 384 635 740 891
966 1,119 1,286 1,345 1,554 1,920 3,164 3,306 3,333 3,841 4,623 5,039
Total Assets 1,893 2,229 2,673 3,008 3,318 3,739 5,625 6,609 6,958 7,667 8,587 9,540

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
-59 197 321 369 293 345 694 823 882 659 540 1,385
-406 -315 -282 -417 -257 -217 -900 -837 -735 -757 -592 -847
486 90 -47 49 -37 -127 243 15 -185 139 59 -551
Net Cash Flow 21 -27 -8 0 -0 0 38 2 -39 41 8 -13
Free Cash Flow -438 -124 50 -12 42 127 98 62 141 293 258 677
CFO/OP -20% 62% 90% 105% 90% 67% 61% 77% 78% 101% 71% 116%

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 78 91 108 100 112 102 98 98 94 124 142 121
Inventory Days 210 177 184 199 201 233 257 279 211 258 258 304
Days Payable 101 91 110 106 144 157 194 140 90 151 138 171
Cash Conversion Cycle 187 177 183 193 169 177 161 237 216 231 262 255
Working Capital Days -0 20 7 -7 9 19 50 57 67 56 56 64
ROCE % 15% 17% 17% 14% 8% 14% 38% 23% 22% 8% 9% 16%

Insights

In beta
Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
API Reactor Capacity
KL

Log in to view insights

Please log in to see hidden values.

Login
Finished Dosage (FDF) Capacity
Billion Units/Year
Cumulative DMF Filings
Number
Cumulative ANDA Filings (US)
Number
Fermentation Capacity
KL
Total R&D and Quality Personnel
Number
CAR-T Therapy Successful Infusions (NexCAR19)
Number
R&D Expenditure (Percentage of Turnover)
%

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

1 Recently
Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
27.20% 27.20% 27.18% 27.18% 27.18% 27.18% 27.62% 27.62% 27.60% 27.60% 27.49% 27.49%
22.52% 24.03% 25.39% 25.98% 25.67% 26.08% 25.56% 25.51% 25.70% 26.17% 26.52% 25.82%
10.36% 11.01% 11.13% 11.78% 13.56% 13.05% 12.74% 11.78% 11.94% 11.72% 12.42% 13.96%
39.93% 37.75% 36.30% 35.07% 33.59% 33.69% 34.09% 35.09% 34.78% 34.52% 33.57% 32.73%
No. of Shareholders 4,17,9774,02,6403,82,8803,56,8303,24,0593,09,0632,92,2142,92,9052,80,2232,83,6782,80,7562,92,281

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings

Concalls